TITLE

Nuclear factor-κB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy

AUTHOR(S)
Marra, Fabio
PUB. DATE
May 2008
SOURCE
Gut;May2008, Vol. 57 Issue 5, p570
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome. It provides an overview of the fatty infiltration of the hepatocytes which characterises non-alcoholic steatohepatitis (NASH). It cites the aspect of NASH which is considered as a possible target for therapy, the inflammation. It also highlights studies on the treatment of NASH.
ACCESSION #
31931723

 

Related Articles

  • Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD). Quercioli, Alessandra; Montecucco, Fabrizio; Mach, Fran�ois // Cardiovascular & Haematological Disorders - Drug Targets;Dec2009, Vol. 9 Issue 4, p261 

    Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of liver damage and alteration of hepatic enzymes. NAFLD is strongly associated with metabolic syndrome and obesity. It is characterized by fat accumulation in the liver that may progress throughout hepatic steatosis and...

  • Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Tsochatzis, Emmanuel A.; Papatheodoridis, George V.; Archimandritis, Athanasios J. // Mediators of Inflammation;2009, Vol. 2009, Special section p1 

    Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and can vary from benign steatosis to end-stage liver disease. The pathogenesis of non-alcoholic steatohepatitis (NASH) is currently thought to involve a multiple-hit process with the first hit being...

  • Metabolic Syndrome Is Associated with Greater Histologic Severity, Higher Carbohydrate, and Lower Fat Diet in Patients with NAFLD. Kang, Hellan; Greenson, Joel K.; Omo, Jason T.; Chao, Cewin; Peterman, Debra; Anderson, Lilian; Foess-Wood, Laura; Sherbondy, Mary A.; Conjeevaram, Hari S. // American Journal of Gastroenterology;Oct2006, Vol. 101 Issue 10, p2247 

    OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic syndrome. Insulin resistance (IR) is a key component of metabolic syndrome. The aim was to determine the dietary composition, physical activity, and histologic severity between NAFLD...

  • Amelioration of Hepatic and Visceral Fat Deposition by Pioglitazone Treatment in Normoglycemic Patients with Metabolic Syndrome. Tsuchiya, Masanobu; Enomoto, Kazuhiro; Nakaoka, Kiyoto; Iijima, Hiroko; Nishio, Yoshihiko; Maegawa, Hiroshi; Kashiwagi, Atsunori // Diabetes;Jun2007 Supplement 1, Vol. 56, pA153 

    Nonalcoholic fatty liver disease (NAFLD) is frequently associated in patients with metabolic syndrome (MS). We recently reported that Pioglitazone (PIO) treatment ameliorated NAFLD in patients with MS. This study was designed to clarify whether amelioration of hyperinsulinemia by PIO treatment...

  • Dietary Manipulation Alters the Phenotype of NAFLD in a Mouse Model - Implications for Human NASH. Subramanian, Savitha; Yeh, Matthew M.; Kowdley, Kris V.; Chait, Alan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA456 

    Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. A "two-hit" hypothesis has been proposed for progression of a normal healthy liver to steatohepatitis (NASH), involving first the development of obesity and insulin resistance (IR) followed by...

  • Role of Secretory Excretory Products of Schistosoma Mansoni Eggs in Modulating Hepatic Morbidity. Rabia, Ibrahim; Fahmy, Zeinab; El-Ahwany, Eman; Sabry, Hoda // Egyptian Journal of Hospital Medicine;Dec2007, Vol. 29, p557 

    In the present study the possible anti-morbidity effect of secretory excretory products (SEP) of Schistoma mansoni eggs (given to mice before infection) was investigated. Multiple small doses of SEP were injected intra-peritoneally into albino mice (100 µg of purified SEP followed 2 weeks...

  • Acute Encephalopathy with Severe Liver Dysfunction.  // Clinical Pediatrics;Mar1969, Vol. 8 Issue 3, p154 

    This article presents a transcript of the Clinical Conference on acute encephalopathy with severe liver dysfunction at St. Louis Children's Hospital in St. Louis, Missouri. The medical panel discussed the indications of which organ systems are malfunctioned and the general categories of the...

  • MANAGEMENT OF "REFRACTORY" ASCITES. Shinaberger, James H.; Galambos, John T. // American Journal of Gastroenterology;May1964, Vol. 41 Issue 5, p499 

    Discusses the management and treatment of refractory ascites in cirrhotic patients. Information on the therapeutic challenges encountered by people with liver diseases; Hepatic and portal hydrodynamic factors associated with ascites formation; Description of the therapy of hepatic and...

  • ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis. Ryder, S D; Beckingham., I J // BMJ: British Medical Journal (International Edition);01/20/2001, Vol. 322 Issue 7279, p151 

    Focuses on acute hepatitis. Identification of an acute hepatic injury by raised alanine transaminase activity; How alkaline phosphatase and ...glutamyltransferase activities can also be raised in patients; Definition of the disease, which normally effects the liver; Impact of a hepatitis...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics